Beckley Psytech

Beckley Psytech is a pioneering, clinical-stage biotechnology company founded in 2019 and headquartered in the United Kingdom. With a clear mission of "Transforming psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions," the company is focused on leveraging decades of scientific research from the Beckley Foundation to address the significant unmet needs in the treatment of depression and other neuropsychiatric disorders.

The company's innovative approach integrates world-class psychedelic science with robust neuropsychiatric drug development expertise, aiming to improve patient outcomes and assimilate clinically validated psychedelic medicines into modern medical practice. The strategic vision is grounded in the belief that such treatments can substantially ease the burden of mental health conditions on both individuals and society at large.

Recently, Beckley Psytech secured a merger investment from ATAI Life Sciences on 01 June 2025, reinforcing the company’s capability to advance its groundbreaking research and expand its clinical pipeline. This investment positions Beckley Psytech as a compelling opportunity for investors seeking impact-driven innovation in the biotechnology sector.